da Vinci Has a New Challenger in Europe. The Question Is Whether It Can Actually Compete.

Cornerstone Robotics raised $200 million in November 2025, per MedTech Dive. Eleven months earlier, it had closed a $70 million round. Total funding: roughly $275 million. The company is seven years old, founded in Hong Kong in 2019, and has never shipped a commercial product outside China.

On May 25, 2026, it received CE Mark certification under the European Union's Medical Device Regulation for its Sentire Endoscopic Surgical System — covering general surgery, gynecology, thoracic, and urology. The clearance formally grants Cornerstone access to European operating rooms.

The timing is not incidental. Intuitive Surgical — the company that has dominated surgical robotics for two decades with its da Vinci system — received CE Mark for its latest-generation da Vinci 5 robot in July 2025. Both systems are now cleared in Europe simultaneously. The incumbent and the challenger arrived in the same window.

"Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider," said Professor Samuel Au, founder and CEO, in the company's announcement. "From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value."

Cornerstone has built something unusual for a company at this stage: actual clinical evidence. A peer-reviewed evaluation of the Sentire C1000 system, published in the Hong Kong Medical Journal in June 2025, assessed the robot in robot-assisted radical prostatectomy across 20 patients between August 2022 and September 2023. Zero procedures required conversion to open surgery. Zero intraoperative complications were attributed to the device. Mean operating time was 184.5 minutes. Median estimated blood loss was 175 milliliters. Median hospital stay was three days.

The trial was small and single-center. It is not a head-to-head comparison with da Vinci. It is, however, peer-reviewed evidence — which is more than most surgical robotics startups have when they announce regulatory milestones.

Cornerstone has also been running a clinical investigation with Portsmouth Hospitals University NHS Trust since 2025, per the PR announcement, covering urology, gynecology, and upper and lower gastrointestinal surgery. The UK subsidiary was formally established in 2025. This is the operational infrastructure the company is now proposing to leverage across Europe.

The path from CE Mark to a European hospital contract is measured in years, not months. Most EU procurement for capital medical equipment runs through public tender processes governed by GPOs — group purchasing organizations that negotiate framework agreements on behalf of hospital networks. A single urology robotics contract can take 18 to 36 months from tender publication to signed agreement, with evaluation committees that include surgeons, procurement officers, and finance. Hospitals that have already committed to a da Vinci service contract — typically five to seven years, running hundreds of thousands of euros annually — have no financial incentive to switch mid-cycle. For those starting fresh, the calculus is not simply which robot is better, but which vendor can train their surgical staff, service their existing infrastructure, and guarantee spare-part logistics for the duration of the contract. Lease models, where the system remains vendor-owned, are increasingly common in European public hospitals precisely because they spread the capital exposure across budget cycles. Cornerstone is walking into a market where the procurement mechanics alone create years of friction before a single surgeon's hands touch the console.

Intuitive Surgical's position is formidable. Da Vinci systems performed approximately 410,000 procedures across Europe in 2024, and nearly 17 million procedures worldwide since the platform debuted. The da Vinci 5, cleared for adult and pediatric use in July 2025, is the first da Vinci system to include force feedback — a feature designed to help surgeons sense the pressure they are applying to tissue, a limitation Intuitive had declined to address for years. Sentire has no published equivalent.

But volume alone does not capture why a hospital sticks with Intuitive. The da Vinci ecosystem is a training and service moat. Surgeons trained on da Vinci carry that certification into their careers; hospitals build proctoring relationships, service agreements, and supply chains around the platform across departments. A hospital that runs 200 da Vinci procedures a year has a nursing staff fluent in the console, a sterile processing team that knows the instrumentation, and a biomed team trained on the system. That institutional knowledge does not transfer when the robot in the room changes. Intuitive's service contracts — typically bundled with the capital lease — also include software updates, remote monitoring, and priority parts replacement. Switching costs are not just financial; they are organizational, and a procurement committee weighing Cornerstone against da Vinci is implicitly voting to retrain an entire surgical department.

Cornerstone's November 2025 raise — led, per earlier reporting, by the Hong Kong Investment Corporation — appears designed to fund the commercial push that CE Mark enables. The question is whether a seven-year-old company with a 20-patient clinical evaluation and a $200 million war chest can meaningfully compete for contracts in a market where the incumbent has performed nearly half a million procedures in Europe in a single year.

The infrastructure suggests intent. The clinical data suggests caution. The funding suggests urgency.

Whether those three things add up to a market shift or a well-financed footnote depends on which European hospitals decide to find out.